Correlation Between China SXT and Shuttle Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both China SXT and Shuttle Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining China SXT and Shuttle Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between China SXT Pharmaceuticals and Shuttle Pharmaceuticals, you can compare the effects of market volatilities on China SXT and Shuttle Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in China SXT with a short position of Shuttle Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of China SXT and Shuttle Pharmaceuticals.

Diversification Opportunities for China SXT and Shuttle Pharmaceuticals

0.52
  Correlation Coefficient

Very weak diversification

The 3 months correlation between China and Shuttle is 0.52. Overlapping area represents the amount of risk that can be diversified away by holding China SXT Pharmaceuticals and Shuttle Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Shuttle Pharmaceuticals and China SXT is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on China SXT Pharmaceuticals are associated (or correlated) with Shuttle Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Shuttle Pharmaceuticals has no effect on the direction of China SXT i.e., China SXT and Shuttle Pharmaceuticals go up and down completely randomly.

Pair Corralation between China SXT and Shuttle Pharmaceuticals

Given the investment horizon of 90 days China SXT Pharmaceuticals is expected to generate 1.43 times more return on investment than Shuttle Pharmaceuticals. However, China SXT is 1.43 times more volatile than Shuttle Pharmaceuticals. It trades about -0.05 of its potential returns per unit of risk. Shuttle Pharmaceuticals is currently generating about -0.08 per unit of risk. If you would invest  1,750  in China SXT Pharmaceuticals on August 24, 2024 and sell it today you would lose (1,712) from holding China SXT Pharmaceuticals or give up 97.83% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

China SXT Pharmaceuticals  vs.  Shuttle Pharmaceuticals

 Performance 
       Timeline  
China SXT Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days China SXT Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Shuttle Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Shuttle Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

China SXT and Shuttle Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with China SXT and Shuttle Pharmaceuticals

The main advantage of trading using opposite China SXT and Shuttle Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if China SXT position performs unexpectedly, Shuttle Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Shuttle Pharmaceuticals will offset losses from the drop in Shuttle Pharmaceuticals' long position.
The idea behind China SXT Pharmaceuticals and Shuttle Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Complementary Tools

Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories